Cheng, L.; Hu, J.; Zhang, L.; Shen, N.; Chen, H.; Zhang, F.
Repurposing Lenvatinib as A Potential Therapeutic Agent against Thyroid Eye Disease by Suppressing Adipogenesis in Orbital Adipose Tissues. Pharmaceuticals 2022, 15, 1305.
https://doi.org/10.3390/ph15111305
AMA Style
Cheng L, Hu J, Zhang L, Shen N, Chen H, Zhang F.
Repurposing Lenvatinib as A Potential Therapeutic Agent against Thyroid Eye Disease by Suppressing Adipogenesis in Orbital Adipose Tissues. Pharmaceuticals. 2022; 15(11):1305.
https://doi.org/10.3390/ph15111305
Chicago/Turabian Style
Cheng, Lu, Jing Hu, Ling Zhang, Ning Shen, Hui Chen, and Fang Zhang.
2022. "Repurposing Lenvatinib as A Potential Therapeutic Agent against Thyroid Eye Disease by Suppressing Adipogenesis in Orbital Adipose Tissues" Pharmaceuticals 15, no. 11: 1305.
https://doi.org/10.3390/ph15111305
APA Style
Cheng, L., Hu, J., Zhang, L., Shen, N., Chen, H., & Zhang, F.
(2022). Repurposing Lenvatinib as A Potential Therapeutic Agent against Thyroid Eye Disease by Suppressing Adipogenesis in Orbital Adipose Tissues. Pharmaceuticals, 15(11), 1305.
https://doi.org/10.3390/ph15111305